CKD-EPI Equations for Glomerular Filtration Rate (GFR)

Uses serum creatinine, serum cystatin C, or both to estimate GFR.

CreatoreDr. Andrew S. Levey, MD
Prova
Preferiti
Istruzioni

 For use in patients with stable, chronic kidney disease to measure kidney function. 

 The 2021 CKD-EPI equation is now the recommended standard. 

  • To improve accuracy the combined creatinine and cystatin C equation is preferred. It is also recommended as a confirmatory test in patients with extreme body composition (e.g. malnourished, amputees, obese patients, high or low muscle mass) and special populations, including pregnancy and diabetes, as creatinine-based estimates are less accurate in these contexts.

  • However, serum cystatin C is not as widely available. The creatinine-based equation is still adequate for many clinical contexts, and is currently recommended for GFR reporting in the United State.

  • Not for use in patients on dialysis.

 

Adjustments based on race

The 2021 versions presented here do not include race but the 2009 and the 2012 CKD-EPI creatinine and creatinine-cystatin C versions do include race. However, adjustments base on race appear to be controversial, and the pros/cons of adjustments ought to be part of a shared decision-making approach between the clinician and the patient. For more information on the topic of eGFR equations and race, NephJC (FitzGerald, 2019) provides an excellent primer on the subject.

* Factors in race (Black or Non-black) into GFR estimate. 

Introduction
CKD-EPI Equations are the standard used to measure kidney function in patients with stable, chronic kidney disease (not acute). These equations use creatinine or a combination of creatinine and cystatin C to measure creatinine clearance as a proxy to estimate glomerular filtration rate(rate). 

The 2021 CKD-EPI creatinine-cystatin C version is the recommended standard and the 2021 CKD-EPI creatinine version is currently recommended by the ASN and NKF for GFR reporting in the United States. However, cystatin C is not available in all laboratories. Yet, the creatinine-based version is adequate for many clinical applications even though the combined creatinine and cystatin C can add accuracy. However, specific populations, such as diabetics, pregnant women, and individuals with unusual body mass (obese, amputees, and severe malnutrition), are at risk for less accurate creatinine-based estimates of kidney function. The 2021 CKD-EPI creatinine-cystatin may offer improved accuracy in these special populations with the addition of cystain C, and is recommended as a confirmatory test in patients with extremes of body composition, to include body fat or muscle mass. CKD-EPI is not indicated for patients on dialysis.

Some of the CKD-EPI equations include adjustments based on race. However, adjustments base on race appear to be controversial and the pros/cons of adjustments ought to be part of a shared decision-making approach between the clinician and the patient. For more information on the topic of eGFR equations and race, NephJC (FitzGerald, 2019) provides an excellent primer on the subject.

The CKD-EPI (creatinine) was developed by Levey et al (2009). 

  • Uses the new gold standard: Clearance of iothalamate

  • Uses linear regression to estimate the logarithm of measured GFR from standardized creatinine levels, sex, race, and age.

2021 CKD-EPI Creatinine

  • = 142 x (Scr/A)^B x 0.9938^age x (1.012 if female)

  • A & B as follows:

Female:

 

Male:

 

Scr ≤ 0.7

A= 0.7

Scr ≤ 0.9 

A= 0.9

 

B= -0.241

 

B= -0.302

 

 

 

 

Scr > 0.7

A= 0.7

Scr > 0.9 

A= 0.9

 

B= -1.2

 

B= -1.2

 

2021 CKD-EPI Creatinine-Cystatin C

  • = 135 x (Scr/A)^B x (Scys/C)^D x 0.9961^age x (0.963 if female)

  • A, B, C & D as follows:

Female:

 

 

 

 

Male:

 

 

 

 

Scr ≤ 0.7

 

Scr > 0.7

 

 

Scr ≤ 0.9

 

Scr > 0.9

Scys ≤ 0.8

A= 0.7

 

A= 0.7

 

Scys ≤ 0.8

A= 0.9

 

A= 0.9

 

B= -0.219

 

B= -0.544

 

 

B= -0.144

 

B= -0.544

 

C= 0.8

 

C= 0.8

 

 

C= 0.8

 

C= 0.8

 

D= -0.323

 

D= -0.323

 

 

D= -0.323

 

D= -0.323

 

 

 

 

 

 

 

 

 

Scys > 0.8

A= 0.7

 

A= 0.7

 

Scys > 0.8

A= 0.9

 

A= 0.9

 

B= -0.219

 

B= -0.544

 

 

B= -0.144

 

B= -0.544

 

C= 0.8

 

C= 0.8

 

 

C= 0.8

 

C= 0.8

 

D= -0.778

 

D= -0.778

 

 

D= -0.778

 

D= -0.778

 

 2009 CKD-EPI Creatinine*

  • = A x (Scr/B)^C x 0.993^Age x (1.159 if black)

  • A, B & C as follows:

Female:

 

Male:

 

Scr ≤ 0.7

A= 144

Scr ≤ 0.9 

A= 141

 

B= 0.7

 

B= 0.9

 

C= -0.329

 

C= -0.411

 

 

 

 

Scr > 0.7

A= 144

Scr > 0.9 

A= 141

 

B= 0.7

 

B= 0.9

 

C= -1.209

 

C= -1.209

 

2012 CKD-EPI Cystatin C 

  • = 133 x (scys/0.8)^A x 0.996^age x B

  • A& B as follows:

Female:

 

 

Male:

Scys ≤ 0.8

A= -0.499

 

A= -0.499

 

B= 0.932

 

B= 1

 

 

 

 

Scys > 0.8

A= -1.328

 

A= -1.328

 

B= 0.932

 

B= 1

 

2012 CKD-EPI Creatinine-Cystatin C*

  • = A x (Scr/B)^C x (Scys/0.8)^D x 0.995^age x (1.08 if Black)

  • A, B, C, & D as follows:

Female:

 

 

 

 

Male:

 

 

 

 

Scr ≤ 0.7

 

Scr > 0.7

 

 

Scr ≤ 0.9

 

Scr > 0.9

Scys ≤ 0.8

A= 130

 

A=130

 

Scys ≤ 0.8

A= 135

 

A= 135

 

B= 0.7

 

B= 0.7

 

 

B= 0.9

 

B= 0.9

 

C= -0.248

 

C= -0.601

 

 

C= -0.207

 

C= -0.601

 

D= -0.375

 

D= -0.375

 

 

D= -0.375

 

D= -0.375

 

 

 

 

 

 

 

 

 

Scys > 0.8

A= 130

 

A= 130

 

Scys > 0.8

A= 135

 

A= 135

 

B= 0.7

 

B= 0.7

 

 

B= 0.9

 

B= 0.9

 

C= -0.248

 

C= -0.601

 

 

C= -0.207

 

C= -0.601

 

D= -0.711

 

D= -0.711

 

 

D= -0.711

 

D= -0.711

*Race may or may not provide better estimates of GFR. Using the adjustment coefficient for black patients is controversial (Inker et al, 2021) and is an optional component.

Abbreviations

  • Scr = serum creatinine (mg/dL)

  • Scys = serum cystatin C (mg/L)

  • GFR = glomerular filtration rate (ml/min/1.73 m²)

 

Chronic Kidney Disease (CKD) Staging

GFR Stage

GFR Description

GFR Range

I

Normal or High

≥90

II

Mildly decreased

60-89

IIIa

Mildly to moderately decreased

45-59

IIIb

Moderately to severely decreased

30-44

IV

Severely decreased

15-29

V

Kidney failure

<15

Source: KIDGO 2012 Clinical Practice Guidelines

Tutte le domande e i risultati possibili

InstructionsTitolo non visibile
Equation

* Factors in race (Black or Non-black) into GFR estimate. 

Select one option:

  • 2021 CKD-EPI Creatinine
  • 2021 CKD-EPI Creatinine-Cystatin C
  • 2009 CKD-EPI Creatinine*
  • 2012 CKD-EPI Cystatin C
  • 2012 CKD-EPI Creatinine-Cystatin C*
Sex

Select one option:

  • Male
  • Female
Age

A number between 0 and 200, in years.

Serum creatinine

A number between 0 and 100, in mg/dL or µmol/L.

Serum cystatin C

A number between 0 and 100, in mg/L.

Race

Optional: Race may or may not provide better estimates of GFR.

Select one option:

  • Black
  • Non-black
Risultati possibili
CKD stage (2012 CKD-EPI Cystatin C)

According to the KDIGO clinical practice guidelines (2012), patients are classified into a CKD stage using both eGFR and albuminuria status. Decreased GFR, increased urinary albumin excretion, or both are considered high risk for progressive kidney disease. Referral to nephrology for further management is indicated for high risk patients.

CKD Stage (2009 CKD-EPI Creatinine)
Estimated GFR (2012 CKD-EPI Cystatin C)
Estimated GFR (2021 CKD-EPI Creatinine-Cystatin C)
Estimated GFR (2021 CKD-EPI Creatinine)
CKD stage (2012 CKD-EPI Creatinine-Cystatin C)

According to the KDIGO clinical practice guidelines (2012), patients are classified into a CKD stage using both eGFR and albuminuria status. Decreased GFR, increased urinary albumin excretion, or both are considered high risk for progressive kidney disease. Referral to nephrology for further management is indicated for high risk patients.

Estimated GFR (2012 CKD-EPI Creatinine-Cystatin C)
CKD Stage (2021 CKD-EPI Creatinine-Cystatin C)

According to the KDIGO clinical practice guidelines (2012), patients are classified into a CKD stage using both eGFR and albuminuria status. Decreased GFR, increased urinary albumin excretion, or both are considered high risk for progressive kidney disease. Referral to nephrology for further management is indicated for high risk patients.

CKD stage (2021 CKD-EPI Creatinine)

According to the KDIGO clinical practice guidelines (2012), patients are classified into a CKD stage using both eGFR and albuminuria status. Decreased GFR, increased urinary albumin excretion, or both are considered high risk for progressive kidney disease. Referral to nephrology for further management is indicated for high risk patients.

Estimated GFR (2009 CKD-EPI Creatinine)

Letteratura